Photo taken from
Chul Kim/X
Jun 2, 2024, 15:18
Chul Kim: PALOMA-3 trial: Significant reduction in IRRs with SC vs. IV in EFGR + NSCLC
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X:
“PALOMA-3 trial: SC vs. IV amivantamab + lazertinib in EGFR-mutant NSCLC.
Similar ORRs, numerically better PFS, improved OS with SC vs. IV.
Significant reduction in IRRs with SC vs. IV (shorter administration time as well)! A great option for patients. ”
Source: Chul Kim/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19